806 related articles for article (PubMed ID: 34664263)
1. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.
Gallagher A; Edwards M; Nair P; Drew S; Vyas A; Sharma R; Marsden PA; Wang R; Evans DJ
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD012929. PubMed ID: 34664263
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
4. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.
Crossingham I; Turner S; Ramakrishnan S; Fries A; Gowell M; Yasmin F; Richardson R; Webb P; O'Boyle E; Hinks TS
Cochrane Database Syst Rev; 2021 May; 5(5):CD013518. PubMed ID: 33945639
[TBL] [Abstract][Full Text] [Related]
5. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
van Geffen WH; Tan DJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
[TBL] [Abstract][Full Text] [Related]
6. Macrolides versus placebo for chronic asthma.
Undela K; Goldsmith L; Kew KM; Ferrara G
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD002997. PubMed ID: 34807989
[TBL] [Abstract][Full Text] [Related]
7. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.
Kew KM; Dahri K
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035
[TBL] [Abstract][Full Text] [Related]
8. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma.
Kew KM; Evans DJ; Allison DE; Boyter AC
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011438. PubMed ID: 26031392
[TBL] [Abstract][Full Text] [Related]
9. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma.
Anderson DE; Kew KM; Boyter AC
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD011397. PubMed ID: 26301488
[TBL] [Abstract][Full Text] [Related]
10. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma.
Chauhan BF; Jeyaraman MM; Singh Mann A; Lys J; Abou-Setta AM; Zarychanski R; Ducharme FM
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010347. PubMed ID: 28301050
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatments for eczema: a network meta-analysis.
Sawangjit R; Dilokthornsakul P; Lloyd-Lavery A; Lai NM; Dellavalle R; Chaiyakunapruk N
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013206. PubMed ID: 32927498
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
13. Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis.
Oba Y; Anwer S; Patel T; Maduke T; Dias S
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD013797. PubMed ID: 37602534
[TBL] [Abstract][Full Text] [Related]
14. Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids.
Ahmad S; Kew KM; Normansell R
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011306. PubMed ID: 26089258
[TBL] [Abstract][Full Text] [Related]
15. Sublingual immunotherapy for asthma.
Fortescue R; Kew KM; Leung MST
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD011293. PubMed ID: 32926419
[TBL] [Abstract][Full Text] [Related]
16. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab for asthma in adults and children.
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
[TBL] [Abstract][Full Text] [Related]
18. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.
Craig SS; Dalziel SR; Powell CV; Graudins A; Babl FE; Lunny C
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012977. PubMed ID: 32767571
[TBL] [Abstract][Full Text] [Related]
19. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.
Fraser A; Poole P
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013343. PubMed ID: 36373977
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
